Two Medicines, Two Approaches
Understanding the Fundamental Difference
Ibogaine and 5-MeO-DMT are both classified as psychedelics, but they operate through fundamentally different pharmacological and experiential pathways. Understanding these differences is essential for choosing the right treatment — or understanding why combining them creates something greater than either alone.
Ibogaine is an indole alkaloid derived from the African shrub Tabernanthe iboga. It acts across multiple receptor systems — opioid, NMDA, serotonin, dopamine, and sigma-2 — producing an extended 18 to 36 hour experience characterized by biographical life review, emotional processing, and receptor-level neuroplasticity. Its primary metabolite, noribogaine, continues working for days after the session, sustaining anti-addictive and neuroplastic effects.
5-MeO-DMT is a tryptamine found in the venom of the Bufo alvarius toad and certain plants. It acts primarily at serotonin 5-HT₁A receptors, producing a rapid 15 to 45 minute experience of complete ego dissolution — not visual hallucinations or narrative processing, but a direct dissolution of the boundary between self and world. Its therapeutic power lies in disrupting the default mode network patterns underlying depression, anxiety, and existential distress.
5-MeO-DMT vs Ibogaine: Complete Comparison
| 5-MeO-DMT | Ibogaine | |
|---|---|---|
| Active Duration | 15-45 minutes | 18-36 hours |
| Primary Mechanism | 5-HT₁A agonism, DMN disruption | Multi-receptor reset (opioid, NMDA, serotonin, sigma-2) |
| Experience Type | Non-dual ego dissolution, pure awareness | Biographical life review, visionary processing |
| Best For | Depression, anxiety, existential distress, spiritual growth | Opioid addiction, withdrawal, PTSD, Parkinson's |
| Addiction Efficacy | Supportive (not primary) | Primary — 85%+ withdrawal elimination in 24h |
| Neuroplasticity | Dendritic growth via 5-HT₁A/₂A (UC Davis) | GDNF/BDNF upregulation (sustained via noribogaine) |
| Cardiac Risk | Minimal — transient HR/BP changes | QTc prolongation — requires continuous EKG monitoring |
| Key Contraindications | MAOIs, lithium, psychosis history | Cardiac conditions, QTc prolongation, certain medications |
| Administration | Inhalation (vaporized) | Oral (capsule) |
| Standalone Cost | $5,000 at MindScape | $7,500-$14,500 at MindScape |
| Integration Period | Hours to days (acute), weeks (full) | Days to weeks (acute), months (full) |
| Research Base | Growing — Johns Hopkins, UC Davis, Maastricht | Established — Noller 2018, Dos Santos 2017, Mash 2000 |
When to Choose Each
Matching the Medicine to Your Needs
Choose Ibogaine If...
You are seeking treatment for opioid addiction, fentanyl dependence, or substance withdrawal. You want a deep biographical processing experience. You have Parkinson's motor symptoms. You need receptor-level neuroplasticity for addiction recovery. Ibogaine is the primary medicine for these applications.
Choose 5-MeO-DMT If...
You are seeking treatment for depression, anxiety, or existential distress. You want a brief but profoundly deep experience. You are pursuing spiritual growth or peak experience. You have tried SSRIs and conventional therapy without sufficient relief. 5-MeO-DMT excels at disrupting the rumination patterns of depression.
Choose Both (Synergistic Protocol) If...
You want the most comprehensive healing available. The ibogaine session provides deep biographical processing, receptor reset, and neuroplasticity. The 5-MeO-DMT session — administered days later into the ibogaine-primed neuroplastic state — adds ego dissolution and existential reorientation. This combination is MindScape's signature offering.
Not Sure Yet?
Every patient at MindScape receives a personalized assessment. Our medical team — led by physicians with 900+ psychedelic treatment sessions — evaluates your condition, history, goals, and contraindications to recommend the optimal protocol. There is no pressure to commit to a specific medicine before screening.
The Synergistic Protocol
Why MindScape Combines Both Medicines
MindScape is one of the only treatment centers in the world offering both ibogaine and 5-MeO-DMT in a carefully sequenced protocol. This is not accidental combination — it is a deliberate pharmacological strategy based on the complementary mechanisms of these two medicines.
Ibogaine initiates a multi-day neuroplastic state through GDNF (glial cell line-derived neurotrophic factor) and BDNF (brain-derived neurotrophic factor) upregulation. During this window of enhanced neural plasticity, the default mode network has already begun structural reorganization. Administering 5-MeO-DMT into this prepared neurological substrate produces a qualitatively different experience than 5-MeO-DMT alone.
The ibogaine session processes the biographical content — childhood patterns, traumatic memories, addiction pathways. The 5-MeO-DMT session dissolves the self-model that organized those patterns in the first place. Together, they address healing at both the narrative and non-dual levels, creating a therapeutic depth unavailable at single-medicine centers.
Following both sessions, NAD+ infusions support cellular recovery and energy restoration. The result is a comprehensive neurological reset that patients and clinicians consistently describe as transformative.
Frequently Asked Questions
5-MeO-DMT vs Ibogaine: Common Questions
Learn More About Our Treatments
Start a Confidential Conversation
100% Confidential · No Obligation · Response Within 24 Hours
100% Confidential · No Obligation · Available 7 Days a Week